immatics’ financial basis is solid, with leading international life science investors endorsing its business. 

With its series A financing round in 2004/2005, immatics has raised more than € 14 million from top tier venture capital firms.

In February 2007, in addition to the existing consortium, Dietmar Hopp as the new lead investor together with new co-investors, committed additional € 40 million to support the success story of immatics. This marks the closing of the largest private biotech financing round in Germany since the year 2001.

INVESTORS

3i Group

-/ www.3i.com

Dievini Hopp BioTech Holding GmbH & Co.KG

EMBL Ventures
-/ www.embl-ventures.com

Grazia Equity
-/ www.grazia-equity.com

KfW Anstalt des öffentlichen Rechts
-/ www.kfw.de

L-EA
-/ www.l-ea.de

Merifin Capital
-/ www.merifin.com

National Technology Enterprises Company
-/ www.ntec.com.kw 

Seed
-/ www.seed-gmbh.de

Vinci Capital/Renaissance
-/ www.vincicapital.ch
-/ www.renaissance-pme.ch

Wellington Partners
-/ www.wellington-partners.com